share_log

Glucotrack Announces Increased Sensor Longevity For Its Implantable Continuous Blood Glucose Monitor

Glucotrack Announces Increased Sensor Longevity For Its Implantable Continuous Blood Glucose Monitor

Glucotrack 宣布延长其植入式连续血糖监测器的传感器寿命
Benzinga ·  04/02 08:35

Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announced

与技术合作伙伴关系进行的计算建模显示,传感器的使用寿命超过3年;比之前宣布的寿命延长了1年

Implantable Continuous Blood Glucose Monitor technology could transform lives of patients with diabetes

植入式连续血糖监测器技术可以改变糖尿病患者的生活

Rutherford, NJ & Cambridge, UK, April 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, and The Technology Partnership ("TTP"), today announced the completion of computational modeling for Glucotrack's implantable Continuous Blood Glucose Monitor ("CBGM"), suggesting sensor longevity beyond three years, a year longer than the Company previously announced.

新泽西州卢瑟福和英国剑桥,2024年4月2日(GLOBE NEWSWIRE)——专注于糖尿病患者新技术设计、开发和商业化的医疗器械公司Glucotrack, Inc.(纳斯达克股票代码:GCTK)(“Glucotrack” 或 “公司”)以及技术伙伴关系(“TTP”)今天宣布完成Glucotrack的计算建模植入式连续血糖监测仪(“CBGM”),表明传感器的使用寿命超过三年,比该公司先前宣布的长一年。

Glucotrack has engaged TTP for the development of computational modeling, which addresses enzyme longevity for use in long-term implantable electrochemical sensors. This in silico modeling specifically evaluated the expected longevity of the Glucotrack CBGM sensor implementation. The CBGM sensor leverages well-established cardiovascular technology to directly measure blood glucose intravenously, providing more rapid glucose monitoring results without the 15-20-minute lag seen with interstitial glucose sensors.

Glucotrack已聘请TTP开发计算建模,该建模可以解决长期植入式电化学传感器中使用的酶寿命问题。这个 在计算机中 建模专门评估了实施Glucotrack CBGM传感器的预期寿命。CBGM 传感器利用成熟的心血管技术,通过静脉注射直接测量血糖,提供更快的血糖监测结果,而不会出现间质葡萄糖传感器出现的 15-20 分钟延迟。

Previously, Glucotrack had announced a projected sensor longevity of 2+ years. TTP's modeling confirmed the 2+ year projection, but TTP's modeling further projects that the Glucotrack CBGM sensor longevity may now be capable of reaching 3+ years. The model developed by TTP captures numerous processes and complex aspects of the sensor function, including the rate of glucose transport in typical in-vivo conditions, the consumption of enzyme, and the impact of reaction components while incorporating appropriate benchtop sensor data.

此前,Glucotrack曾宣布传感器的预计使用寿命为2年以上。TTP的建模证实了2年以上的预测,但TTP的建模进一步预测,Glucotrack CBGM传感器的使用寿命现在可能达到3年以上。TTP 开发的模型捕捉了传感器功能的众多过程和复杂方面,包括典型的葡萄糖转运速率 活体 条件、酶消耗以及反应成分的影响,同时纳入适当的台式传感器数据。

TTP brings over 35 years of experience in the life science and healthcare sectors to this project, with specific expertise in multiphysics modeling, electrochemical sensor development, and the design and integration of wearable and implantable medical devices. TTP's knowledge and skills have been instrumental in evaluating and extending the projected longevity of the Glucotrack CBGM sensor.

TTP 为该项目带来了生命科学和医疗保健领域超过 35 年的经验,在多物理场建模、电化学传感器开发以及可穿戴和植入式医疗设备的设计和集成方面拥有专业知识。TTP的知识和技能在评估和延长Glucotrack CBGM传感器的预计寿命方面发挥了重要作用。

"TTP is well versed in supporting clients with creating breakthrough medical technology solutions," said Paul Goode, PhD, CEO of Glucotrack. "This collaboration has enhanced our development program, and the projected increase in sensor longevity to beyond three years further demonstrates that our technology is truly differentiated in the glucose monitoring space. This achievement doesn't change our commercialization timing but instead paves the way for future generations of our system, which will be a truly long-term CBGM to people living every day with diabetes."

Glucotrack首席执行官保罗·古德博士表示:“TTP精通支持客户创建突破性的医疗技术解决方案。”“这种合作加强了我们的开发计划,预计传感器的使用寿命将延长至三年以上,这进一步表明我们的技术在葡萄糖监测领域确实与众不同。这一成就并没有改变我们的商业化时机,而是为我们系统的子孙后代铺平了道路,对于每天生活在糖尿病患者来说,这将是真正的长期CBGM。”

Chris Dawson, PhD, Head of Biosensing at TTP, said: "We are delighted to be working on this exciting and disruptive technology with Glucotrack. These tremendously promising results, coupled with Glucotrack's innovative approach to glucose monitoring, means that this technology has the potential to deliver a new way for patients to manage their diabetes with discretion and minimal disruption to their lives."
For more information about Glucotrack's CBGM, visit glucotrack.com.

TTP生物传感负责人克里斯·道森博士表示:“我们很高兴与Glucotrack合作开发这项令人兴奋的颠覆性技术。这些非常有希望的结果,加上Glucotrack创新的血糖监测方法,意味着这项技术有可能为患者提供一种全新的方式,使他们能够谨慎地管理糖尿病,最大限度地减少对生活的干扰。”
有关 Glucotrack CBGM 的更多信息,请访问 glucotrack.com。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发